SEARCH

SEARCH BY CITATION

REFERENCES

  • 1
    Srivastava T Alon US The role of bisphosphonates in diseases of childhood. Eur J Pediatr 2003 162: 735751.
  • 2
    Adami S Bhalla AK Dorizzi R Montesanti F Rosini S Salvagno G Lo Cascio V The acute-phase response after bisphosphonate administration. Calcif Tissue Int 1987 41: 326331.
  • 3
    Schweitzer DH Oostendorp-van de Ruit M Van der Pluijm G Löwik CW Papapoulos SE Interleukin-6 and the acute phase response during treatment of patients with Paget's disease with the nitrogen-containing bisphosphonate dimethylaminohydroxypropylidene bisphosphonate. J Bone Miner Res 1995 10: 956962.
  • 4
    Sauty A Pecherstorfer M Zimmer-Roth I Fioroni P Juillerat L Markert M Ludwig H Leuenberger P Burckhardt P Thiebaud D Interleukin-6 and tumor necrosis factor alpha levels after bisphosphonates treatment in vitro and in patients with malignancy. Bone 1996 18: 133139.
  • 5
    Thiébaud D Sauty A Burckhardt P Leuenberger P Sitzler L Green JR Kandra A Zieschang J Ibarra de Palacios P An in vitro and in vivo study of cytokines in the acute-phase response associated with bisphosphonates. Calcif Tissue Int 1997 61: 386392.
  • 6
    Olson K Van Poznak C Significance and impact of bisphosphonate-induced acute phase responses. J Oncol Pharm Pract 2007 13: 223229.
  • 7
    Thompson K Rogers MJ Statins prevent bisphosphonate-induced γδT-cell proliferation and activation in vitro. J Bone Miner Res 2004 19: 278288.
  • 8
    Hewitt RE Lissina A Green AE Slay ES Price DA Sewell AK The bisphosphonate acute phase response: Rapid and copious production of proinflammatory cytokines by peripheral blood γδ T cells in response to aminobisphosphonates is inhibited by statins. Clin Exp Immunol 2005 139: 101111.
  • 9
    De Maria M Mogorovich A Giannarini G Manassero F Selli C Lidocaine-prilocaine administration during transrectal ultrasound-guided prostatic biopsy: A randomized, single-blind, placebo-controlled trial. J Endourol 2006 20: 525529.
  • 10
    Senn S 2002 The AB/BA design with normal data. In: SennS (ed.) Crossover Trials in Clinical Research, 2nd ed. John Wiley and Sons, Hoboken, NJ, USA 3588.
  • 11
    Högler W Yap F Little D Ambler G McQuade M Cowell CT Short-term safety assessment in the use of intravenous zoledronic acid in children. J Pediatr 2004 145: 701704.
  • 12
    Munns CF Rajab MH Hong J Briody J Högler W McQuade M Little DG Cowell CT Acute phase response and mineral status following low dose intravenous zoledronic acid in children. Bone 2007 41: 366370.
  • 13
    Thompson Healthcare 2004 Zometa. Physician Desk Reference. 58th ed. Thompson Healthcare, Montvale, NJ, USA.
  • 14
    Grilo RM Treves R Preux PM Vergne-Salle P Bertin P Clinically relevant VAS pain score change in patients with acute rheumatic conditions. Joint Bone Spine 2007 74: 358361.
  • 15
    Giraudeau B Rozenberg S Valat JP Assessment of the clinically relevant change in pain for patients with sciatica. Ann Rheum Dis 2004 63: 11801181.
  • 16
    Bird SB Dickson EW Clinically significant changes in pain along the visual analog scale. Ann Emerg Med 2001 38: 639643.